Dana-farber-cancer Institute Inc.

Columbia University

The United States of America As Represented by the Department of Health

Behringwerke Aktiengesellschaft

New England Deaconess Hospital Corporation

Cambridge Bioscience Corporation

William A Haseltine

Joseph G Sodroski

Craig A Rosen

Wayne A Marasco

Wei C Goh

Ernest Terwilliger

Eric Cohen

Andrew Lever

Mark Poznansky

Craig D Furman

Udy Olshevsky

Eirik Helseth

Flossie Wong-Staal

John H Li

Dante J Marciani

Richard Wyatt

Stephen P Goff

Gerald A Beltz

Naoko Tanese

Chung-Ho Hung

Marshall R Posner

Richard M Thorn

Ralph Grassmann

Norman Letvin

Joseph G Sodrowski

Marie-Christine Dokhelar

Kathleen McGuire

Ingrid Muller-Fleckenstein

Bernard Fleckenstein

Heinrich Gottlinger

Yinchen Lu

Markus Thali

Suresh K Arya

Christopher M Farnet

The present invention relates to a method by which one can target an undesired target molecule or target antigen, preferably a protein. The method comprises the intracellular expression of an antibody capable of binding to the target. A DNA sequence is delivered to a cell, the DNA sequence contains a sufficient number of nucleotides coding for the portion of an antibody capable of binding to the target operably linked to a promoter that will permit expression of the antibody in the cell(s) of interest. The antibody is then expressed intracellularly and binds to the target, thereby disrupting the target from its normal actions.

Method of intracellular binding target molecules

Method of intracellular binding of target molecules

A vector comprising an HIV segment and a heterologous gene segment, which produces a replication competent and an infective HIV virus is disclosed. When the heterologous gene is a marker gene, the spread of the virus can be observed in both in vitro and in vivo systems. The use of this vector in establishing methods for screening anti-viral compounds is also disclosed.

Vector comprising a replication competent HIV-1 provirus and a

Packaging defective and packaging proficient HIV vectors are disclosed. These vectors can be used to establish HIV packaging defective cell lines, and to package desired genes. These cell lines can be used in developing a vaccine, HIV antibodies and as part of a system for gene transfer. The packaging proficient vector can be used to target HIV target cells.

Vectors containing HIV packaging sequences, packaging defective HIV

Immunogenic peptides containing amino acid residues which define a binding site to a CD4 receptor are disclosed. Antibodies to these peptides are also disclosed. Methods of reducing the ability of a gp12O env protein to bind to CD4 are also disclosed. Methods of treatment and prophylaxis using these antibodies and peptides are also described.

Immunogenic peptides, antibodies and uses thereof relating to CD4

The present invention is directed to a recombinant human monoclonal antibody which binds to a discontinuous epitope on the HIV gp120 envelope glycoprotien, blocks the binding of gp120 to the CD4 receptor, and neutralizes a broad range of HIV isolates. The present invention also provides the primary nucleotide and deduced amino acid sequences of the rearranged heavy and light chains of the recombinant monoclonal antibody of the present invention, and a method of screening for antibodies which block binding of envelope glycoprotein to the CD4 receptor.

Reactive neutralizing human anti-GP120 recombinant antibody, DNA coding

Immunogenic peptides containing amino acid residues which define a binding site to a CD4 receptor are disclosed. Antibodies to these peptides are also disclosed. Methods of reducing the ability of a gp120 env protein to bind to CD4 are also disclosed. Methods of treatment and prophylaxis using these antibodies and peptides are also described.

Assays screened for compounds that inhibit tat transactivation of the HIV (HTLV-III) LTR are taught. The assay involves tranfecting a cell line containing the tat gene by a vector containing a gene under the control of an HIV-1 LTR, adding the compound to be screened and determining the effect of the compound by looking at the effect of tat as measured by the expression of the gene under the control of the HIV LTR.

Assay methods for tat cell lines

Nucleic acid encoding a functional HTLV-III/LAV (HIV-1) protein having trans-activating ability, and expression vectors comprising this nucleic acid are described.

Nucleic acid encoding HIV-1 tat protein

An assay for factors that affect integration of DNA into target DNA is disclosed. Assays for methods of screening for factors which effect viral DNA circularization either by homologous recombination, end-to-end ligation, or autointegration, are also disclosed. A method for screening for factors which will enhance circularization rather than integration by testing cellular cytoplasmic fluid under conditions which permit circularization in the fluid is also described. Factors which effect integration and circularization are disclosed. Therapeutic methods for retarding viral infection are also described.

Assays for factors affecting circularization of DNA, assays for factors

A vector which can be used to establish a hybrid SIV/HIV-1 virus is described. This virus can be used to infect an animal such as a monkey to establish an animal model for in vivo testing. This animal model can be used for purposes such as screening for therapeutics, adjuvants and vaccines.

Vectors expressing hybrid viruses, methods of use and novel assays

Isolated and purified YC1 genes and proteins are disclosed. The protein binds to a site in the HIV-LTR, the NRE-1 site, and can inhibit the expression of a gene operably linked to the HIV-1 LTR. The use of the protein and gene are discussed. Repressible and inducible expression systems using the YC1 gene are also disclosed.

YC1 gene

Growing community of inventors

Cambridge, MA, United States of America

William A Haseltine